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descriptorsAbstract Alzheimer’s disease (AD) is a chronic neurodegenerative disease. Current therapies of AD
are only symptomatic, therefore the need for the development of new therapies to treat Alzheimer’s
disease effectively. To achieve this objective quantitative structure–activity relationship (QSAR) stud-
ies were carried out as it provides the rationale for the changes in the structure to have more potent
Ab42 inhibitors or anti-Alzheimer’s agents. Quantitative structure–activity relationship (QSAR) stud-
ies were carried out on a series of 34 fused 5,6-bicyclic heterocycles to investigate the structural
requirements of their inhibitory activity against Ab42. The statistically signiﬁcant best 3D-QSAR
model having cross-validated squared correlation coefﬁcient q2 = 0.8457 with external predictive
ability of pred_r2 = 0.7556 was developed by SW-kNN. Developed kNN–MFA model highlighted
the importance of shape of the molecules, i.e., hydrophobic and steric descriptors at the grid points
H_83 and S_183, S_227 for c-secretase binding interaction. This model (3D) was found to yield reli-
able clues for further optimization of fused 5,6-bicyclic heterocycles in the data set. The information
An approach to design potent anti-Alzheimer’s agents by 3D-QSAR studies on fused 5,6-bicyclic heterocycles 925rendered by the 3D-QSARmodelmay lead to a better understanding of the structural requirements of
c-secretase modulators and can also help in the design of novel potent c-secretase modulators.
ª 2013 Production and hosting by Elsevier B.V. on behalf of King Saud University.1. Introduction
AD is a neurodegenerative disorder associated with difﬁculties
in memory, judgment, abstraction, and language (Kim and
Kim, 2008). More than 35 million people suffer from AD
worldwide, with an estimated annual cost of over $600 billion,
and the AD population may increase to more than 115 million
by the year 2050 according to a report from Alzheimers Dis-
ease International (Sun et al., 2012). Alzheimer’s disease
(AD) symptoms are dementia, apraxia, aphasia, depression,
short attention span, visuospatial navigation deﬁcits, anxiety
and delusions (Harvey et al., 2011). The majority of AD cases
are sporadic, with disease onset after 65 years of age
(Iijima-Ando and Iijima, 2010). Key molecules involved in
AD, include the presenilins, amyloid precursor protein, tau,
and b-amyloid (Balaraman et al., 2006).
Alzheimer’s disease (AD) is the biggest unmet medical need
in neurology due to the lack of disease-modifying anti-
Alzheimer’s drugs (DMAADs) (Kreft et al., 2008). Over the last
decade, c-secretase emerged as a promising target for the treat-
ment of AD (Xin et al., 2011). It has been postulated that mod-
ulation of c-cleavage to favor the production of shorter
fragments, while not affecting total Ab levels,might be a safe ap-
proach to a disease-modifying therapy (Fischer et al., 2011). c-
Secretase activity can be controlled by the inhibition of the active
site of PS1or by interferencewith complex assembly or substrate
recognition, the latter resulting in allosteric modulation or inhi-
bition. The allosteric mechanisms are particularly attractive tar-
gets for drug development (Narlawar et al., 2007), as they may
produce shorter, soluble, and non-toxic peptides (e.g., Ab36–
Ab40) instead of the highly insoluble and neurotoxic Ab42,
without interfering in the processing of Notch and other sub-
strates (Caldwell et al., 2010). c-Secretase modulators (GSMs)
modulate the cleavage of the APP C-terminal fragment such as
C-99 to decrease Ab42 and increase the shorter Ab fragments
(e.g., Ab37/38) while not affecting the cleavage of other sub-
strates such as Notch (Fischer et al., 2011). The fact that an in-
crease as small as 30% in the levels of Ab42 can cause familial
AD suggests that loweringAb42 by a similar amount could have
a disease-modifying effect. This suggests that this degree of
Notch-sparing selectivity may be sufﬁcient to avoid mecha-
nism-based toxicity (Kreft et al., 2008).
c-Secretase modulation is more desirable than inhibition
from a therapeutic perspective and may reduce the risk of
mechanism-based toxicities (Xin et al., 2011). Such com-
pounds, called Notch-sparing GSIs (NS-GSIs) or c-secretase
modulators (GSMs), would be good candidates for AD thera-
peutics (Kurosumi et al., 2010).
Computational chemistry has developed into an important
contributor to rational drug design. Molecular modeling study
is an approach used to narrow down a library containing an
extraordinarily high number of random molecules into a smal-
ler list of potentially effective inhibitors. The techniques of
QSAR are valuable molecular modeling tools for drug design.
The quantitative structure activity relationship (QSAR)
approach became very useful and largely widespread for theprediction of biological activities, particularly in drug design.
The QSAR method provides a rational basis for understanding
mechanisms of biological performance and shows how to
improve performance by altering chemical structures of
ligands, which has been proved to be one of the most embraced
computational approaches in modern drug discovery
(Bhadoriya et al., 2012b; Chen et al., 2009; Jain et al.,
2012a,b,c). Quantitative structure activity relationship (QSAR)
is one of the major tools in drug discovery to explore ligand–
receptor/enzyme interactions, especially when either the
structural details of the target are not known or protein binding
data of ligand is unavailable. Quantitative structure–activity
relationship (QSAR) studies leading to models in terms of
chemical structures and their biological activities produce use-
ful information for drug design and medicinal chemistry. 2D-
QSAR does not involve complex alignment or assumptions
on conformations (Joshi et al., 2010). 3D-QSAR is a broad
term encompassing all those QSAR methods which correlate
macroscopic target properties with computed atom-based
descriptors derived from the spatial (3D) representation of
the molecular structures (Verma et al., 2010). The 3D-QSAR
protocols have been selected with a view to understand the li-
gand–receptor interaction in the light of steric, electrostatic
and hydrophobic properties (Ghosh and Bagchi, 2009a). Three
dimensional quantitative structure activity relationship (3D-
QSAR) is a widely used tool to identify the steric, electrostatic,
and hydrophobic structural requirements of various drugs act-
ing via receptor modulation for exerting biological activity.
Development of the 3D-QSAR model based on the biological
activity of compounds enables ligand-based drug design that
guides experimental chemical synthesis of compounds with
higher potency even when the 3D structure of the biological tar-
get is unknown (Bhadoriya et al., 2012a,b,d; Mathura et al.,
2010; Sharma et al., 2012).
Previously, we have reported 2D-QSAR studies on a series
of fused 5,6-bicyclic heterocycles such as c-secretase modula-
tors (GSMs) with classical 2D descriptors. MLR method was
used to generate statistically signiﬁcant 2D-QSAR models
(Bhadoriya et al., 2012c). Now, in continuation with our ear-
lier work, we report 3D-QSAR studies on such a series of fused
5,6-bicyclic heterocycles with classical 3D descriptors. The
present work is an attempt to generate predictive 3D-QSAR
models based on 3D-QSAR methods and to ﬁnd the structural
features of fused 5,6-bicyclic heterocycles as c-secretase modu-
lators (GSMs) required for Ab42 inhibitory activities to guide
the rational synthesis of novel c-secretase modulators (GSMs).
3D-QSAR ﬁeld descriptors i.e. steric, electrostatic and hydro-
phobic are useful for the better understanding of molecular
modeling studies of this series of compounds in terms of
ligand–receptor interactions. In this investigation, a widely
used technique, viz. stepwise (SW) has been applied for
descriptor optimization, and kNN–MFA analysis has been ap-
plied for 3D-QSAR model development. The developed model
provides insight into the inﬂuence of various interactive ﬁelds
on the activity and, thus, can help in designing and forecasting
the Ab42 inhibitory activities of fused 5,6-bicyclic heterocycles.
Table 1 Structures of dataset used for kNN–MFA QSAR analysis with corresponding observed and predicted Ab42 inhibitory
activities of fused 5,6-bicyclic heterocycles as c-secretase modulators.
NN
CH3
O
CH3 X
N
Y
N
R
GSM1-GSM21
NN
CH3
O
CH3 X Y
N
R
GSM22-GSM34
.
Compound_ID R X Y Observed activity
Ab42IC50 (nM)
Observed activity
(Ab42pIC50)
Stepwise forward kNN–MFA
Predicted Activity
(Ab42pIC50)
Residual
GSM1 H N N 20,000 4.70 4.7 0
GSM2
F
CH3
N N 509 6.29 6.31 0.02
GSM3a
F
CH3
N N 156 6.81 6.94 0.13
GSM4
F
CH3
N N 145 6.84 6.94 0.1
GSM5
F
N N 16,374 4.79 4.7 0.09
GSM6 N N 20,000 4.70 4.79 0.09
GSM7a
F
N N 649 6.19 6.21 0.02
GSM8
F
F
F
CH3
N N 342 6.47 6.79 0.32
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Table 1 (continued)
Compound_ID R X Y Observed activity
Ab42IC50 (nM)
Observed activity
(Ab42pIC50)
Stepwise forward kNN–MFA
Predicted Activity
(Ab42pIC50)
Residual
GSM9
F
CH3
F
F
N N 116 6.94 6.84 0.1
GSM10a
F
F N N 552 6.26 6.31 0.05
GSM11a
Cl
Cl N N 126 6.90 6.35 0.55
GSM12
CN
N N 2531 5.60 5.65 0.05
GSM13
O
CH3
N N 1409 5.85 6.21 0.36
GSM14 F N N 619 6.21 5.85 0.36
GSM15 N N 1406 5.85 6.06 0.21
GSM16
F
O N N 19,316 4.71 5.65 0.94
GSM17a F
O
N N 1919 5.72 5.6 0.12
GSM18 F
O
CH3
N N 485 6.31 6.29 0.02
GSM19 O
CH3
N N 2069 5.68 5.6 0.08
GSM20
N
O
O
N N 20,000 4.70 4.7 0
An approach to design potent anti-Alzheimer’s agents by 3D-QSAR studies on fused 5,6-bicyclic heterocycles 927
Table 1 (continued)
Compound_ID R X Y Observed activity
Ab42IC50 (nM)
Observed activity
(Ab42pIC50)
Stepwise forward kNN–MFA
Predicted Activity
(Ab42pIC50)
Residual
GSM21
S
F
O O
N N 2215 5.65 5.6 0.05
GSM22
F
CH3
O N 465 6.33 6.27 0.06
GSM23a CH3
O N 537 6.27 6.03 0.24
GSM24a
F
O N 356 6.45 6.7 0.25
GSM25 F
F
O N 440 6.36 6.84 0.48
GSM26a
F
CH3
N O 1392 5.86 6.03 0.17
GSM27
F
CH3
N O 448 6.35 6.03 0.32
GSM28
F
CH3
N O 875 6.06 5.85 0.21
GSM29 CH3
F
F
N O 935 6.03 6.35 0.32
GSM30 CH3
F
F
F
N O 540 6.27 6.33 0.06
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Table 1 (continued)
Compound_ID R X Y Observed activity
Ab42IC50 (nM)
Observed activity
(Ab42pIC50)
Stepwise forward kNN–MFA
Predicted Activity
(Ab42pIC50)
Residual
GSM31 CH3
F
N NH 164 6.79 6.84 0.05
GSM32
F
F
F
CH3
N NH 201 6.70 6.91 0.21
GSM33
F
F
F
CH3
N NH 122 6.91 6.7 0.21
GSM34
F
F
F
CH3
N NH 209 6.68 6.27 0.41
a Indicates the compounds considered in the test set, rest of the compounds considered in the training set for the 3D-QSAR study.
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The molecular modeling studies (3D-QSAR) were carried out
on a Windows XP workstation using the molecular modeling
software package VLife Molecular Design Suite (VLifeMDS)
version 3.5 (VLife MDS 3.5, 2008).
2.1. Biological activity dataset for analysis
A set of 34 fused 5,6-bicyclic heterocycles as c-secretase mod-
ulators (GSMs) reported by Qin et al. (Qin et al., 2011), were
selected for Ab42 inhibitory activity requirements. The struc-
tures, biological activity and predicted activity data are given
in Table 1. Ab42 inhibitory activity was reported as IC50 in
nM units. For the 3D-QSAR study the reported IC50 was
converted to negative logarithm (pIC50) in molar units and
subsequently used as the dependent variable for the 3D-QSAR
analysis.
2.2. Computational details
The structures of the fused 5,6-bicyclic heterocycles considered
for 3D-QSAR study were sketched on Chem sketch 12.0 soft-
ware (ACD/Chemsketch 12.0, 2009). All structures were
cleaned and 3D optimized. The energy optimization of the
molecules was performed by batch calculation in VLife MDS
3.5 software (VLife MDS 3.5, 2008) using Merck MolecularForce Field (MMFF) (Halgren,1996a,b,c,d, 1999a,b) with dis-
tance dependent dielectric function and an energy gradient of
0.001 kcal/mol A˚.
2.3. Conformation generation of molecules
It is a well recognized fact that each compound containing one
or more single bonds is existing at each moment in many dif-
ferent so-called rotamers or conformers. Although small mol-
ecules may have only a single lowest energy conformation
large and ﬂexible molecules do exist in multiple conformations
at physiological conditions. Therefore, it becomes necessary to
include various such conformations of the molecules in a 3D-
QSAR study (Verma et al., 2010). Multiple conformations of
each molecule were generated using a Monte Carlo conforma-
tional search with an RMS gradient of 0.001 kcal/mol using a
MMFF. Monte Carlo search method is a random search meth-
od for ﬁnding conformations of molecules (Metropolis et al.,
1953). The low energy conformer for each compound was se-
lected for further 3D-QSAR study.
2.4. Alignment of molecules
The alignment of molecules is the process of aligning two or
more molecules in 3D space to optimally superimpose speciﬁc
atoms on each other based on distances (Vyas and Ghate,
2012). One of the most crucial problems in most of the align-
Figure 2 Stereo view of template based alignment of fused 5,6-
bicyclic heterocycles on the base template.
930 K.S. Bhadoriya et al.ment-based 3D-QSAR methods is that their results are highly
sensitive to the manner in which the bioactive conformations
of all the molecules are superimposed over each other. In cases,
where all the molecules in a data set have a common rigid core
structure, molecules can be aligned easily using the
least-square ﬁtting procedure. However in the case of struc-
tural heterogeneity in the dataset, alignment of highly ﬂexible
molecules becomes quite difﬁcult and time consuming (Verma
et al., 2010). The position of each atom is important for the
kNN–MFA study because the descriptors calculation is based
on the 3D-space grid. Thus, the method to determine the con-
formation of each molecule and the way to align molecules to-
gether are two sensitive input parameters and determining
factors to build a reasonable and a reliable model (Bhadoriya
et al., 2012d). A proper alignment of the structures is a crucial,
critical and decisive step for obtaining effective and valid 3D-
QSAR models. Improper or incorrect alignment of molecules
can create models providing little information relating to the
main orientation of the molecule in the active site (Telvekar
et al., 2010). Energy-minimized and geometry-optimized struc-
tures of molecules were aligned by the template-based method
(Ajmani et al., 2006), where a template structure is deﬁned and
used as a basis for the alignment of a set of molecules, and a
reference molecule is chosen on which the other molecules of
the data set get aligned considering the chosen template. The
template structure, i.e. 1-(2-methoxyphenyl)-4-methyl-1H-
imidazole ring, was used for the alignment by considering
the common elements of the series as shown in Fig. 1. The ref-
erence molecule is chosen in such a way that it is the most ac-
tive among the series of molecules considered. The compound
GSM9 possessed very high Ab42 inhibitory activity which
made it a valid lead molecule and, therefore, was chosen as a
reference molecule. After optimizing, the template structure
and the reference molecule were used to superimpose all mol-
ecules from the series using the template alignment method in
VLife MDS 3.5 software (VLife MDS 3.5, 2008) to obtain
optimal alignment between the molecular structures necessary
for ligand–receptor/enzyme interactions. The superimposition
of all molecules based on minimizing RMS deviation is shownFigure 1 1-(2-Methoxyphenyl)-4-methyl-1H-imidazole ring as a
common template used for template based alignment of fused 5,6-
bicyclic heterocycles as c-secretase modulators.in Fig. 2. The resulting alignments of molecules were used for
building kNN–MFA 3D-QSAR models.
2.5. Calculation of molecular ﬁeld descriptors for 3D-QSAR
analysis
Molecular ﬁeld analysis (MFA) was employed to derive the
3D-QSAR model in this study. Molecular ﬁeld analysis
(MFA) model is predictive and sufﬁciently reliable to guide
the chemist in designing novel compounds. This approach is
effective for the analysis of data sets, where activity informa-
tion is available but the structure of the receptor site is
unknown (Silakari et al., 2011). After superimposition, the
overlaid set of molecules is positioned in the center of a lattice
or grid box, to calculate interaction energies between the li-
gands and different probe atoms placed at each intersection
of the lattice (Verma et al., 2010). The aligned biologically ac-
tive conformations of fused 5,6-bicyclic heterocycles were used
for the calculation of molecular ﬁelds. Molecular ﬁelds are the
electrostatic, steric and hydrophobic interaction energies which
were computed at the lattice points of the grid using a methyl
probe of charge +1 considering Gasteiger–Marsili charges
(Gasteiger and Marsili, 1980). 10.0 kcal/mol electrostatic cut-
off and 30.0 kcal/mol steric cut-off was employed to perform
descriptor calculation. The term descriptor is utilized to indi-
cate ﬁeld values at the lattice points. These interaction energy
values are considered for relationship generation and utilized
as descriptors to decide nearness between molecules. A value
of 1.0 is assigned to the distance-dependent dielectric constant.
A total of 5577 three dimensional descriptors were calculated
using VLife MDS software. These included electrostatic, steric
and hydrophobic ﬁeld descriptors (1859 for each electrostatic,
steric and hydrophobic descriptor) for all the compounds in
separate columns.
2.6. Design of the training and test sets using SEM (sphere
exclusion method)
In order to obtain a validated QSAR model for the purpose of
meaningful prediction, an available dataset should be divided
into training and test sets. For the prediction statistics to be
reliable, the test set must include at least ﬁve compounds
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tion of the data set of 34 molecules into training and test sets
comprising of 26 and 8 molecules, respectively, was performed
by the rational sphere exclusion (SE) method with a dissimilar-
ity value of 2.23. The dissimilarity value gives the sphere exclu-
sion radius. For sphere exclusion algorithm, pIC50 activity was
used as a dependent variable and various calculated electro-
static, steric and hydrophobic ﬁeld 3D molecular descriptors
as independent descriptors. Sphere exclusion algorithm allows
constructing training sets covering all descriptor space areas
occupied by representation points. The test set compounds
should represent structural diversity and a range of biological
activities similar to that of the training set. Compounds in the
test set allowed us to use one test compound over three train-
ing compounds, thus resulting in more rigorous validation of
the training model. In addition, a wide range of structural
diversity of compounds in the test set permitted us to evaluate
the extrapolative accuracy of the 3D-QSAR models. The test
set molecules captured structural features of the training set
molecules, thus their activities could be well predicted. Train-
ing set of 26 compounds and a test set of eight compounds
were used for generating 3D-QSAR models and for validating
the quality of the models, respectively. Sphere exclusion ap-
proach resulted, eight compounds, namely GSM3, GSM7,
GSM10, GSM11, GSM17, GSM23, GSM24, and GSM26 as
the test set and the remaining 26 compounds as the training
set (Table 1).
2.7. Stepwise forward as variable (feature) selection method
The problem that is faced frequently by a researcher in devel-
oping QSAR models is that of a small number of observations
(molecules) compared with a large number of molecular
parameters in the descriptor pool. Recent trends in QSAR
have focused on the development of procedures that allow
the selection of optimal variables with low complexity and
good predictive accuracy from the available pool of descriptors
of chemical structures, i.e. the ones that are most meaningful
and statistically signiﬁcant in terms of correlation with biolog-
ical activity. This process forms the basis of a technique known
as feature selection or variable selection (Guyon and Elisseeff,
2003; Ghosh and Bagchi, 2009b; Sahu et al., 2011). Our ﬁrst
objective was to determine the best variables which produce
the most signiﬁcant 3D-QSAR models linking the structure
of compounds with their binding afﬁnity. Among several
search algorithms, SW forward variable selection algorithm
coupled with kNN–MFA was used to establish the 3D-QSAR
models. In the SW forward variable selection algorithm, the
search procedure begins with developing a trial model step
by step with a single independent variable and to each step,
independent variables are added one at a time, examining
the ﬁt of the model by using the kNN–MFA procedure. Thus,
the model is repeatedly altered from the previous one by add-
ing or removing a predictor variable in accordance with the
‘stepping criteria’ (in this case, F= 4 for inclusion for the for-
ward selection method). The method continues until there is no
signiﬁcant variable remaining outside the model.
In the selected equations, the cross-correlation limit was set
at 0.5, the number of variables at 10 and the term selection cri-
teria at r2. An F value was speciﬁed to evaluate the signiﬁcance
of a variable. The variance cut-off was set at 0.0, and scaling as
none. Additionally the kNN parameter setting was done inwhich the number of maximum neighbors and the number of
minimum neighbors were set at 5 and 2, respectively and the
prediction method was selected as the distance-based weighted
average.
2.8. k-Nearest neighbor molecular ﬁeld analysis method for
generating 3D-QSAR models
In order to predict binding domain of c-secretase, a k-nearest
neighbor (kNN) classiﬁcation model was developed. The k-
nearest neighbor (kNN) method is one of the simplest machine
learning algorithms, most commonly used for classifying a new
pattern (e.g. a molecule) (Verma et al., 2010). The kNN tech-
nique is a conceptually simple approach to pattern recognition
problems (VLife MDS 3.5, 2008). k-Nearest neighbor molecu-
lar ﬁeld analysis (kNN–MFA) is the 3D-QSAR method which
has been used to produce the 3D models to indicate the regions
that affect biological activity with a change in the chemical sub-
stitution (Sharma et al., 2012). The kNNmethodology relies on
a simple distance learning approach whereby an unknown/new
member is classiﬁed according to the majority of its k-nearest
neighbors in the training set. The nearness is measured by an
appropriate distance metric (e.g., a molecular similarity mea-
sure calculated using ﬁeld interactions of molecular structures).
The standard kNN method is implemented simply as follows:
(1) Calculate the distances between an unknown object (u)
and all the objects in the training set;
(2) Select k objects from the training set most similar to
object u, according to the calculated distances; and
(3) Classify object u with the group to which the majority of
the k objects belongs (Sharaf et al., 1986). An optimal k
value is selected by optimization through the classiﬁca-
tion of a test set of samples or by leave-one-out cross-
validation.
The variables and optimal k values were chosen using step-
wise variable selection method. This method employs a step-
wise variable selection procedure combined with kNN to
optimize
(i) The number of nearest neighbors (k) and
(ii) The selection of variables from the original pool.
2.9. k-Nearest neighbor QSAR (kNN weighted average method)
The kNNmethod was also used to develop a QSARmodel using
continuousvariable, i.e. usingactivity aspIC50values. In this case,
byusing adevelopedkNNQSARmodel the activity of amolecule
can be predicted using weighted average activity (Eq. (1)) of k
most similar molecules in the training set.
y^i ¼
X
wiyi ð1Þ
where yi and yˆi are the actual and predicted activities of the
ith molecule respectively, and wi is weight calculated using
(Eq. (2)).
wi ¼ expðdjÞXk
j¼1
expðdjÞ
ð2Þ
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tances (dj) between molecules (Eq. (3)) using only the subset of
descriptors corresponding to the model, where, k is the number
of nearest neighbors in the model.
di;j ¼
XVn
m¼1
ðXi;m  Xj;mÞ
" #1=2
ð3Þ
where, X is the matrix of the selected descriptors (Vn) for the
kNN QSAR model.
2.10. Model validation and evaluation
This is done to test the internal stability and predictive ability
of the QSAR models.
2.10.1. Internal and external validations
Internal validation was carried out using the leave-one-out (q2,
LOO) method. For calculating q2, each molecule in the train-
ing set was sequentially eliminated, the model reﬁt using same
descriptors, and the biological activity of the eliminated mole-
cule predicted using the reﬁt model. The cross-validated coef-
ﬁcient, q2, was calculated using Eq.(4).
q2 ¼ 1
Pðyi  y^iÞPðyi  ymeanÞ2 ð4Þ
where yi and yˆi are the actual and the predicted activity of the
ith molecule in the training set, respectively, and ymean is the
average activity of all molecules in the training set.
However, a high q2 value does not necessarily give a suit-
able representation of the real predictive power of the model
for c-secretase modulators. So, an external validation is also
carried out in this study. The external predictive power of
the model is assessed by predicting pIC50 value of eight test
set molecules, which are not included in the 3D-QSAR model
development. The predictive ability of the selected model is
also conﬁrmed by pred_r2.
For external validation, activity of each molecule in the test
set was predicted using the model generated from the training
set. The pred_r2 value is calculated as follows (Eq. (5))
Pred r2 ¼ 1
Pðyi  y^iÞ2Pðyi  ymeanÞ2 ð5Þ
where yi and yˆi are the actual and the predicted activities of the
ith molecule in the test set, respectively, and ymean is the aver-
age activity of all molecules in the training set.
Both summations are over all molecules in the test set. Thus
the pred_r2 value is indicative of the predictive power of the
current kNN–MFA model based on the external test set.
2.10.2. Randomization test
Y-randomization (randomization of response) is a widely used
approach to establish the model robustness. It consists of
repeating the calculation procedure with randomized activities
and subsequent probability assessment of the resultant statis-
tics. Frequently, it is used along with cross-validation
(Golbraikh and Tropsha, 2002b). The robustness of the mod-
els for training sets was examined by comparing these models
to those derived for random data sets. Random sets were gen-
erated by rearranging the activities of the molecules in the
training set. The signiﬁcance of the models hence obtained
was derived based on a calculated Zscore; Eq. (6).A Zscore value is calculated using the following formula:
Zscore ¼ ðh lÞ
r
ð6Þ
where h is the q2 value calculated for the actual data set, l is
the average q2, and r is its standard deviation calculated for
various iterations using models built by different random data
sets.
The probability (a) of signiﬁcance of the randomization test
is derived by using calculated Zscore value as given in the lit-
erature (Shen et al., 2003).
2.10.3. Evaluation of the quantitative model
The developed 3D-QSAR model was evaluated using the fol-
lowing statistical measures: N, number of observations (mole-
cules) in the training set; number of nearest neighbors, number
of k-nearest neighbors in the model; q2, cross-validated r2 (by
leave one out) which is a relative measure of quality of ﬁt;
pred_r2, r2 for external test set; q2se, standard error of cross-
validation and pred_r2se, standard error of external test set
prediction. However, a QSAR model is considered to be pre-
dictive, if the following conditions are satisﬁed: q2 > 0.6 and
pred_r2 > 0.5 (Golbraikh and Tropsha, 2002a). The low stan-
dard error of pred_r2se and q2se shows absolute quality of ﬁt-
ness of the model. The high pred_r2 and low pred_r2se show
high predictive ability of the model.
The q2 and pred_r2 values were used as deciding factors in
selecting the optimal models.3. Results and discussion
The 3D-QSAR study of 34 fused 5,6-bicyclic heterocycles for
Ab42 inhibitory activity (Table 1) through kNN methodology,
based on SW feature selection method using VLife MDS 3.5
software (VLife MDS 3.5, 2008), resulted in the following sta-
tistically signiﬁcant model, considering the term selection crite-
rion as q2 and pred_r2. The training and test set compounds
(Table 1) for this group of compounds were selected by the
sphere exclusion method, and the model was validated by both
internal and external validation procedures.
Selection of compounds in the training set and test is a key
and important feature of any QSAR model. Therefore care
was taken in such a way that biological activities of all com-
pounds in the test lie within the maximum and minimum value
range of biological activities of the training set of compounds.
The UniColumn Statistics of test and training sets further re-
ﬂected the correct selection of test and training sets (Table 2).
The maximum and minimum values in the training and test
sets were compared in a way that:
1. The maximum value of pIC50 of the test set should be less
than or equal to the maximum value of pIC50 of the train-
ing set.
2. The minimum value of pIC50 of the test set should be higher
than or equal to the minimum value of pIC50 of the training
set.
This observation showed that the test set was interpolative
and derived within the minimum–maximum range of the train-
ing set. The mean and standard deviation of pIC50 values of
sets of training and test provide insights into the relative differ-
Table 4 Descriptors used in 3D-QSAR model with values.
Compound_ID Observed activity
(Ab42pIC50)
H_83 S_183 S_227
GSM1 4.70 0.191522 0.326565 0.090766
GSM2 6.29 0.305327 0.331884 0.089395
GSM3 6.81 0.332995 0.332539 0.089892
GSM4 6.84 0.341568 0.335532 0.091112
GSM5 4.79 0.31945 0.338717 0.080566
GSM6 4.70 0.323797 0.330989 0.088111
GSM7 6.19 0.286387 0.331192 0.087782
GSM8 6.47 0.346581 0.32725 0.093112
GSM9 6.94 0.338179 0.331278 0.094365
GSM10 6.26 0.31265 0.334265 0.092369
GSM11 6.90 0.365571 0.331393 0.092395
GSM12 5.60 0.271679 0.328204 0.09097
GSM13 5.85 0.287434 0.334026 0.08554
GSM14 6.21 0.285316 0.332226 0.08714
GSM15 5.85 0.307373 2.682489 0.085977
GSM16 4.71 0.279406 0.328525 0.08907
GSM17 5.72 0.26086 0.331234 0.088706
GSM18 6.31 0.312223 0.32969 0.091833
GSM19 5.68 0.276221 0.986976 0.091342
GSM20 4.70 0.189483 0.338925 0.091308
GSM21 5.65 0.274999 0.332262 0.09314
GSM22 6.33 0.389735 0.331284 0.093743
GSM23 6.27 0.360056 0.334452 0.092105
GSM24 6.45 0.373484 0.334879 0.09559
GSM25 6.36 0.334969 0.335777 0.083753
GSM26 5.86 0.35857 0.339599 0.083049
GSM27 6.35 0.358021 0.327903 0.089254
GSM28 6.06 0.391041 3.574147 0.093438
GSM29 6.03 0.355705 0.332605 0.087771
GSM30 6.27 0.400326 0.334155 0.095092
GSM31 6.79 0.347824 0.333944 0.092523
GSM32 6.70 0.380233 0.333618 0.083544
GSM33 6.91 0.371048 0.329226 0.082761
GSM34 6.68 0.403634 0.336324 0.083096
Table 2 Unicolumn statistics of the training and test sets for Ab42 inhibitory activity.
Data set Column name Average Max. Min. SD Sum
Training Ab42pIC50 5.9912 6.9400 4.7000 0.7349 155.7700
Test Ab42pIC50 6.3075 6.9000 5.7200 0.4117 50.4600
Max., maximum; Min., minimum; SD, standard deviation.
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the two sets. The mean of the test sets was higher than the
training sets that indicates the presence of relatively more ac-
tive molecules as compared to the inactive ones. Also, a rela-
tively higher standard deviation in training sets indicates that
training sets had widely distributed activity of the molecules
as compared to the test sets (VLife MDS 3.5, 2008).
Statistically signiﬁcant best 3D-QSAR model was selected,
considering the term selection criterion as q2, the internal pre-
dictive ability of the model and pred_r2, the ability of the mod-
el to predict the activity of the external test set. Best 3D-QSAR
model is chosen for discussion.
3.1. 3D-QSAR modeling and its validation
Various 3D-QSAR models were developed using the kNN
method. In the present study, kNN coupled with stepwise vari-
able selection method was used to develop 3D-QSARmodels of
fused 5,6-bicyclic heterocycles with reported Ab42 inhibitory
activities based on hydrophobic and steric ﬁelds. Several statis-
tically signiﬁcant 3D-QSAR models were generated, of which
the corresponding best model is reported herein. 3D-QSAR
model was selected based on the value of statistical parameters
and the best kNN–MFA 3D-QSAR model with 26 training set
compounds have a q2 = 0.8457 and pred_r2 = 0.7556 (Table 3).
The descriptors selected for 3D-QSAR modeling Ab42
inhibitory activity of fused 5,6-bicyclic heterocycles are sum-
marized in Table 4 and the correlation matrix between the
hydrophobic and steric descriptors inﬂuencing the Ab42 inhib-
itory activity is presented in Table 5.
The actual/observed activities, predicted activities by 3D-
QSAR model and residuals of both training and test sets com-
pounds are given in Table 1. The plots of observed versus pre-
dicted activity of both training and test sets compounds helped
in cross-validation of the kNN–MFA QSAR model and are
depicted in Fig. 3. The residuals of the kNN–MFA calculated
values of pIC50 are plotted against the observed activity (Ab42-
pIC50) values in Fig. 4. The propagation of residuals at bothTable 3 Statistical results of the 3D-QSAR model generated
by stepwise forward variable selection kNN–MFA method for
fused 5,6-bicyclic heterocycles as c-secretase modulators.
S. No. Statistical parameter 3D-QSAR results
1 q2 0.8457
2 q2se 0.2887
3 pred_r2 0.7556
4 pred_r2se 0.2634
5 Ntraining 26
6 Nearest neighbor 2
7 Degree of freedom 22
8 Contributing descriptors 1. H_83 (0.3416, 0.3466)
2. S_183 (0.3355, 0.3273)
3. S_227 (0.0931, 0.0911)
Table 5 Correlation matrix for steric and hydrophobic
descriptors inﬂuencing the Ab42 inhibitory activity (3D-QSAR
model).
S_183 S_227 H_83 Score
S_183 1 0.10075 0.118567 3
S_227 0.10075 1 0.088562 3
H_83 0.118567 0.088562 1 3sides of the zero line indicates that no systematic error exists
in the development of the kNN–MFA model.
The model selection criterion is the value of q2, the internal
predictive ability of the model and that of pred_r2, the ability
of the model to predict the activity of the external test set. For
Ab42 inhibitory activity, selected model was found to be statis-
tically most signiﬁcant, especially with respect to the internal
predictive ability (q2 = 0.8457) of the model. As the cross-
Figure 4 Scatter plot of the observed activity (Ab42pIC50) versus
residuals for training set & test set compounds.
Figure 3 Comparison of observed activity versus predicted
activity for the training set & test set compounds according to the
3D-QSAR SW-kNN–MFA model.
Figure 5 SW-kNN–MFA model ﬁeld plot for hydrophobic and
steric ﬁeld interactions.
934 K.S. Bhadoriya et al.validated correlation coefﬁcient (q2) is used as a measure of the
reliability of prediction, the correlation coefﬁcient suggests
that our model is reliable and accurate. A data set of eight
compounds was selected as the test set from the original data
of 34 compounds for the validation experiments. The value
of pred_r2 was obtained for the test set and gave better results,
with a value of 0.7556, which means 76% predictive power for
the external test set. Thus, our model displays good predictiv-
ity in regular cross-validation (Table 3.).
H_83, S_227, and S_183 are the hydrophobic and steric
ﬁeld energy of interactions. The above model is validated by
predicting the biological activities of the test set molecules,
as indicated in Table 1.
The plot of observed versus predicted activities for the test
compounds is represented in Fig. 3. From Table 1. it is evident
that the predicted activities of all the compounds in the test set
are in good agreement with their corresponding experimental
activities and optimal ﬁt is obtained.
The external predictability of the above 3D-QSAR model
using the test set was determined by pred_ r2, which is
0.7556. So, the above results indicate that 3D-QSAR model
for c-secretase modulators generate 84.57% and 75.56% inter-
nal and external model predictions, respectively.3.1.1. Hydrophobic and steric ﬁeld plot
The plot of contributions of hydrophobic and steric ﬁeld inter-
actions (Fig. 5) indicates relative regions of the local ﬁelds
(hydrophobic and steric ﬁeld) around the aligned molecules.
Yellow and green balls represent hydrophobic and steric ﬁeld
effects, respectively.
In the QSAR model, hydrophobic descriptor with positive
coefﬁcients represents regions of high hydrophobic tolerance.
Steric descriptors with negative coefﬁcients indicate regions
where the bulky substituent is disfavored.
From the 3D-QSAR model (Fig. 5) it is observed that the
steric ﬁeld with negative coefﬁcient (S_183) at the methyl posi-
tion of the imidazole ring indicate that bulky substituents are
unfavorable on this site and the presence of bulky substituents
decrease the activity of fused 5,6-bicyclic heterocycles. Presence
of another steric ﬁeld with negative coefﬁcient (S_227) at the
methoxy position of the benzene ring suggests that bulky sub-
stituents are unfavorable on this site and the presence of bulky
substituents decrease the activity of fused 5,6-bicyclic heterocy-
cles. Hydrophobic ﬁeld with positive coefﬁcient (H_83) near the
methoxy position of the benzene ring indicates that more
hydrophobic groups in this position would have a beneﬁcial ef-
fect on the anti-Alzheimer’s activity of these fused 5,6-bicyclic
heterocycles. Thus, the contribution plot arising out of
3D-QSAR studies provide some useful insights for better
understanding of the structural features of these compounds
responsible for producing signiﬁcant Ab42 inhibitory activities.
4. Conclusions
In conclusion, the present study highlights the importance of
the structural features responsible for the Ab42 inhibitory
activity. A 3D-QSAR study of a set of fused 5,6-bicyclic het-
erocycles has been performed. Stepwise forward variable selec-
tion algorithm has been applied for variable selection and the
models were developed by the kNN–MFA method. Reliability
of the models was conﬁrmed by several statistical analyses. For
the dataset of 34 fused 5,6-bicyclic heterocycles, shape of the
substituents i.e., steric and hydrophobic descriptors of the mol-
ecules appear to be the governing factor for the Ab42 inhibi-
tory activity. The present investigation will guide the
synthetic medicinal chemist to design and synthesize new novel
more potent Ab42 inhibitors (anti-Alzheimer’s agents) with in-
An approach to design potent anti-Alzheimer’s agents by 3D-QSAR studies on fused 5,6-bicyclic heterocycles 935creased biological activity in comparison to the reported com-
pounds. In future, continuation with this work docking studies
will be performed on this particular dataset of 34 fused 5,6-
bicyclic heterocycles by using receptor–ligand-co-crystal struc-
tures available in the protein data bank.Acknowledgements
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